Table 1.

Risk stratification models for venous thromboembolism (VTE) risk in cancer patients. Adapted with permission from Song et al. [13].

Score	Incorporated Risk Factors
Khorana score (KS) [14]	Tumor site of origin: Very high risk: stomach, pancreas High risk: lung, lymphoma, gynecologic, bladder, testicular Prechemotherapy platelet count ≥350 × 109/L Hemoglobin level < 10 g/dL or use of erythropoiesis-stimulating agents Prechemotherapy leukocyte count > 11 × 109/L Body mass index ≥35 kg/m2
Vienna CATS score [7]	KS plus the following: Soluble P-selectin >53.1 ng/L D-dimer ≥1.44 µg/L
PROTECHT score [8]	KS plus the following: Use of platinum-based therapy Use of gemcitabine
CONKO score [9]	Tumor site of origin: Very high risk: stomach, pancreas High risk: lung, lymphoma, gynecologic, bladder, testicular Prechemotherapy platelet count ≥350 × 109/L Hemoglobin level < 10 g/dL or use of erythropoiesis-stimulating agents Prechemotherapy leukocyte count > 11 × 109/L WHO performance status ≥2
Tic-ONCO score [10]	Tumor site of origin: Very high risk: stomach, pancreas High risk: lung, lymphoma, gynecologic, bladder, testicular Genetic risk score (germline polymorphisms in F5, F13 or SERPINA10) Body mass index > 25 kg/m2 Family history of VTE
ONKOTEV score [15]	KS > 2 Metastatic cancer Personal history of VTE Macroscopic vascular or lymphatic compression
COMPASS-CAT score [16]	Breast, lung, ovarian or colorectal cancer only Cancer-related risk factors: Anthracycline or anti-hormonal therapy in women with breast cancer Time since cancer diagnosis ≤6 months Central venous catheter Advanced cancer stage Predisposing risk factors: Cardiovascular risk factors (≥2 of peripheral artery disease, ischemic stroke, coronary artery disease, hypertension, hyperlipidemia, diabetes, obesity) Recent hospitalization for acute medical illness Personal history of VTE Prechemotherapy platelet count ≥350 × 109/L